Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks

NCT01934790 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01934790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01934790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Completed
Start date
December 22, 2013
Completion date
April 12, 2017
Enrollment
45 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms